Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposphostasia.
Company Details
- Employees
- 8
- Address
- 2901, Rachel Street East, #23, Montreal,quebec H1w 4a4,canada
- Phone
- +1 203-272-2596
- he****@****try.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- enobia.com
- HQ
- Montreal, Quebec
Enobia Pharma Questions
Enobia Pharma's helpline number is +1 203-272-2596
Enobia Pharma's website is enobia.com
Enobia Pharma's LinkedIn profile is https://www.linkedin.com/company/enobia-pharma
Enobia Pharma has
8 employees.
View email and phone details for 8
employees at Enobia Pharma.
Enobia Pharma's industry is
Biotechnology Research
Enobia Pharma's top competitors are
Tesaro, Inc.,
Ice Pharma Group,
Bear Valley Mountain Resort,
Prometic Bioproduction Inc.,
Immuni T,
Spri Clinical Trials,
Gsk,
Novelion Therapeutics,
Scanlab Photogrammetry,
Alexion Pharmaceuticals, Inc..
Enobia Pharma's support email address is help@laldeficiencyregistry.com
Enobia Pharma's categories are Biotechnology Research
